THERAPY DOSSIER · th-3900aa7ef6a4

JC1-40

Drug · No ChEMBL record under the code JC1-40 and no chemical name given in the source abstract, so unresolvable by synonym search. No ClinicalTrials.gov record (searched, not assumed).

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: No ChEMBL record under the code JC1-40 and no chemical name given in the source abstract, so unresolvable by synonym search. No ClinicalTrials.gov record (searched, not assumed).
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31409825 ↗2019Reported benefit

RORalpha suppresses interleukin-6-mediated hepatic acute phase response.

MouseChemical/toxinC57BL/6NMaleOral gavage20 mg/kg/day in 0.5% carboxymethyl cellulosePretreatment for 3 days before diethylnitrosamine injection

Model: Acute liver injury and hepatic acute-phase response induced by a single intraperitoneal injection of diethylnitrosamine 100 mg/kg

JC1-40 reduced diethylnitrosamine-induced serum transaminases, TNF-alpha and IL-1beta without changing serum IL-6, attenuated periportal apoptosis and DNA damage, and reduced leucocyte infiltration. Hepatic acute-phase gene expression fell by 35 to 45%, with lower phosphorylated STAT3 and reduced I…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…